Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion

Publisher： John Wiley & Sons Inc

E-ISSN： 1755-148x|28|5|607-610

ISSN： 1755-1471

Source： PIGMENT CELL & MELANOMA RESEARCH, Vol.28, Iss.5, 2015-09, pp. : 607-610

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS‐mutant and wild‐type melanoma

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 31, Iss. 1, 2018-01 ,pp. : 110-114

John Wiley & Sons Inc

Access to resources Recommend Favorite

Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 31, Iss. 2, 2018-03 ,pp. : 341-344

John Wiley & Sons Inc

Access to resources Recommend Favorite

The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitors

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 4, 2015-07 ,pp. : 417-430

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma

By Chan Xian Yang   Singh Alamdeep   Osman Narin   Piva Terrence J.  

International Journal of Molecular Sciences, Vol. 18, Iss. 7, 2017-07 ,pp. : 1527-1527

MDPI

Access to resources Recommend Favorite

MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 3, 2015-05 ,pp. : 254-266

John Wiley & Sons Inc

Access to resources Recommend Favorite